Clinical Overview of Omacor: A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids

      Omacor (omega-3-acid ethyl esters; Reliant Pharmaceuticals, Inc., Liberty Corner, NJ) is a highly purified, prescription omega-3 fatty acid formulation with high concentrations of eicosapentaenoic acid (EPA) (465 mg) and docosahexaenoic acid (DHA) (375 mg) in each 1-g capsule, along with 4 mg (6 IU) of vitamin E. At a typical dose of 4 capsules/day, Omacor significantly lowers plasma triglyceride levels either as monotherapy or in combination with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) or fibrates. Omacor also modestly increases plasma levels of low-density lipoprotein cholesterol, increases high-density lipoprotein cholesterol levels, and has favorable effects on lipoprotein particle size and subclass distribution. Omacor is well tolerated, with few side effects other than mild gastrointestinal symptoms. Hyperglycemia, abnormal bleeding, elevations in muscle or liver enzymes, and/or abnormalities in kidney or nerve function have not been reported. Through its intensive purification process, Omacor has minimal “fishy” smell and taste, and it has not been reported to cause hypervitaminosis or illness due to exposure to environmental toxins. Omacor provides a safe, effective, well-tolerated approach to management of hypertriglyceridemia.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. American Heart Association. Fish and omega-3 fatty acids [AHA Recommendation]. Available at: Accessed January 27, 2006.

      2. United States Department of Agriculture, Agricultural Research Service Nutrient Data Laboratory. Available at: Accessed January 27, 2006.

        • Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico
        Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction.
        Lancet. 1999; 354: 447-455
        • Grundt H.
        • Nilsen D.W.
        • Hetland O.
        • Aarsland T.
        • Baksaas I.
        • Grande T.
        • Woie L.
        Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia.
        J Intern Med. 1995; 237: 249-259
        • Eritsland J.
        • Arnesen H.
        • Gronseth K.
        • Fjeld N.B.
        • Abdelnoor M.
        Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency.
        Am J Cardiol. 1996; 77: 31-36
        • Harris W.S.
        • Ginsberg H.N.
        • Arunakul N.
        • Shachter N.S.
        • Windsor S.L.
        • Adams M.
        • Berglund L.
        • Osmundsen K.
        Safety and efficacy of Omacor in severe hypertriglyceridemia.
        J Cardiovasc Risk. 1997; 4: 385-391
        • McKeone B.J.
        • Osmundsen K.
        • Brauchi D.
        • Pao Q.
        • Payton-Ross C.
        • Kilinc C.
        • Kummerow F.A.
        • Pownall H.J.
        Alterations in serum phosphatidylcholine fatty acyl species by eicosapentaenoic and docosahexaenoic ethyl esters in patients with severe hypertriglyceridemia.
        J Lipid Res. 1997; 38: 429-436
        • Abe Y.
        • El-Masri B.
        • Kimball K.T.
        • Pownall H.
        • Reilly C.F.
        • Osmundsen K.
        • Smith C.W.
        • Ballantyne C.M.
        Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion.
        Arterioscler Thromb Vasc Biol. 1998; 18: 723-731
        • Pownall H.J.
        • Brauchi D.
        • Kilinc C.
        • Osmundsen K.
        • Pao Q.
        • Payton-Ross C.
        • Gotto Jr, A.M.
        • Ballantyne C.M.
        Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.
        Atherosclerosis. 1999; 143: 285-297
        • Johansen O.
        • Brekke M.
        • Seljeflot I.
        • Abdelnoor M.
        • Arnesen H.
        • Coronary Angioplasty Restenosis Trial
        N-3 fatty acids do not prevent restenosis after coronary angioplasty.
        J Am Coll Cardiol. 1999; 33: 1619-1626
        • Calabresi L.
        • Donati D.
        • Pazzucconi F.
        • Sirtori C.R.
        • Franceschini G.
        Omacor in familial combined hyperlipidemia.
        Atherosclerosis. 2000; 148: 387-396
        • Westphal S.
        • Orth M.
        • Ambrosch A.
        • Osmundsen K.
        • Luley C.
        Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids.
        Am J Clin Nutr. 2000; 71: 914-920
        • Stalenhoef A.F.
        • de Graaf J.
        • Wittekoek M.E.
        • Bredie S.J.
        • Demacker P.N.
        • Kastelein J.J.
        The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
        Atherosclerosis. 2000; 153: 129-138
        • Durrington P.N.
        • Bhatnagar D.
        • Mackness M.I.
        • Morgan J.
        • Julier K.
        • Khan M.A.
        • France M.
        An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
        Heart. 2001; 85: 544-548
        • Calabresi L.
        • Villa B.
        • Canavesi M.
        • Sirtori C.R.
        • James R.W.
        • Bernini F.
        • Franceschini G.
        An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia.
        Metabolism. 2004; 53: 153-158
        • Kaminski W.E.
        • Jendraschak E.
        • Kiefl R.
        • von Schacky C.
        Dietary omega-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells.
        Blood. 1993; 81: 1871-1879
        • Eritsland J.
        • Arnesen H.
        • Berg K.
        • Seljeflot I.
        • Abdelnoor M.
        Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation.
        Scand J Clin Lab Invest. 1995; 55: 295-300
        • Russo C.
        • Olivieri O.
        • Girelli D.
        • Azzini M.
        • Stanzial A.M.
        • Guarini P.
        • Friso S.
        • De Franceschi L.
        • Corrocher R.
        Omega-3 polyunsaturated fatty acid supplements and ambulatory blood pressure monitoring parameters in patients with mild essential hypertension.
        J Hypertens. 1995; 13: 1823-1826
        • Donadio Jr, J.V.
        • Larson T.S.
        • Bergstralh E.J.
        • Grande J.P.
        A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy.
        J Am Soc Nephrol. 2001; 12: 791-799
      3. US Department of Health and Human Resources and the US Environmental Protection Agency. What you need to know about mercury in fish and shellfish: 2004 EPA and FDA advice for: women who might become pregnant, women who are pregnant, nursing mothers, young children. Publication No. EPA-823-R-04-005. Available at:∼dms/admehg3.html. Accessed January 27, 2006.

      4. Solvay Healthcare Limited. Omacor Production. Solvay Public Omacor Website. Available at: Accessed January 27, 2006.

      5. Omacor [prescribing information]. Liberty Corner, NJ: Reliant Pharmaceuticals, Inc; 2005. Available at: Accessed April 7, 2006.